Kate Grindlay, Juno Obedin-Maliver, Sachiko Ragosta, Jen Hastings, Mitchell R Lunn, Annesa Flentje, Matthew R Capriotti, Zubin Dastur, Micah E Lubensky, Heidi Moseson
BACKGROUND: In July 2023, the US Food and Drug Administration approved the first non-prescription oral contraceptive, a progestin-only pill, in the United States. Transgender, nonbinary, and gender-expansive people assigned female or intersex at birth face substantial contraceptive access barriers and may benefit from over-the-counter oral contraceptive access. However, no prior research has explored their perspectives on this topic. OBJECTIVE: To measure interest in over-the-counter progestin-only pill use among transgender, nonbinary, and gender-expansive individuals assigned female or intersex at birth...
February 14, 2024: American Journal of Obstetrics and Gynecology